Intercept Pharmaceuticals ICPT incurred a loss of 14 cents per share (from continuing operations) in second-quarter 2023, narrower than the Zacks Consensus Estimate of 56 cents. The company also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback